6-溴苯并[D]噁唑 | 375369-14-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 中文名称: 6-溴苯并[D]噁唑
• 中文别名: 6-溴苯并噁唑；6-溴苯并恶唑；6-溴苯并[D]唑；6-溴苯并[D]1,3-氧氮杂茂；6-溴苯并[D]恶唑
• 英文名称: 6-bromobenzo[d]oxazole
• 英文别名: 6-bromobenzoxazole；6-bromo-1,3-benzoxazole
• CAS: 375369-14-5
• 化学式: C₇H₄BrNO
• 分子量: 198.019
• InChiKey: YXVFVHLEIBLKCA-UHFFFAOYSA-N

物化性质

• 沸点：
  251.2±13.0 °C(Predicted)
• 密度：
  1.710±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  储存条件：室温、密封、干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromobenzoxazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromobenzoxazole
CAS number: 375369-14-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H4BrNO
Molecular weight: 198.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

6-溴苯并[D]噁唑是一种杂环有机化合物，可作为医药中间体使用。

反应信息

• 作为反应物：
  描述：

  6-溴苯并[D]噁唑 在 甲醇 、 sodium tetrahydroborate 、 甲酸 、 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 10.17h， 生成
  参考文献：
  名称：

  一类泛-KRAS抑制剂及其制备和应用

  摘要：

  本发明提供了一类作为泛‑KRAS抑制剂的四氢异喹啉类衍生物，具体地，本发明提供了一类结构式如通式(I)所示的四氢异喹啉类衍生物，及其药学上可接受的盐，其对泛‑KRAS具有抑制活性。本发明还提供了此类衍生物的制备方法，其药物组合物、成盐复合物、以及作为泛‑KRAS抑制剂在治疗不同种类肿瘤中的医学用途。

  公开号：

  CN114874201A
• 作为产物：
  描述：

  2-氨基-5-溴苯酚 、 原甲酸三甲酯 在 对甲苯磺酸 作用下， 反应 1.0h， 以93%的产率得到6-溴苯并[D]噁唑
  参考文献：
  名称：

  [EN] IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
  [FR] COMPOSÉS IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX

  摘要：

  本发明提供了取代的咪唑[1,5-a]嘧啶基甲酰胺及其相关有机化合物，包含此类化合物的组合物，医疗试剂盒，以及使用此类化合物和组合物治疗医疗障碍的方法，例如，戈谢病，帕金森病，路易体病，痴呆症或多系统萎缩症。本说明书中描述的代表性的取代咪唑[1,5-a]嘧啶基甲酰胺化合物包括取代的2-杂环基-4-烷基-咪唑[1,5-a]嘧啶-8-甲酰胺化合物及其变体。

  公开号：

  WO2017176961A1

文献信息

• [EN] PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF<br/>[FR] HERBICIDES CARBOXYLATES DE PYRIDINE ET DE PYRIMIDINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：DOW AGROSCIENCES LLC

  公开号：WO2019084353A1

  公开（公告）日：2019-05-02

  Provided herein are pyridine and pyrimidine carboxylates and their derivatives, and compositions and methods of use thereof as herbicides.

  本文提供吡啶和嘧啶羧酸盐及其衍生物，以及它们作为除草剂的组合物和使用方法。
• 小分子PD-1/PD-L1抑制剂、其与PD-L1抗体的药物组合物及其应用
  申请人：上海再极医药科技有限公司

  公开号：CN111714628A

  公开（公告）日：2020-09-29

  本发明公开了一种小分子PD‑1/PD‑L1抑制剂、其与PD‑L1抗体的药物组合物及其应用。其中，该小分子PD‑1/PD‑L1抑制剂例如通式(I)所示的芳香乙烯或芳香乙基类衍生物，其可以用于治疗癌症。
• [EN] PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS EN TANT QUE MODULATEURS DES RÉCEPTEURS DES PGE2
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2018210988A1

  公开（公告）日：2018-11-22

  The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式(I)的嘧啶衍生物，其中(R1)n，R3，R4a，R4b，R5a，R5b和Ar1如描述中所述，以及它们通过调节免疫反应，包括肿瘤中免疫系统的再激活，用于治疗癌症。本发明进一步涉及新颖的苯并呋喃和苯并噻吩衍生物式(II)，及其作为药物的使用，其制备，药用可接受的盐，及其作为药物的使用，以及包含式(I)中一个或多个化合物的药物组合物，尤其是它们作为前列腺素2受体EP2和/或EP4的调节剂的使用。
• [EN] 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIDINE 2,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE TGF-BÊTA ET PROCÉDÉS D'UTILISATION
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2015157093A1

  公开（公告）日：2015-10-15

  The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

  本发明涉及的化合物包括公式（IV）的化合物，以及一种治疗癌症的方法，包括向患有癌症的受试者施用其中一种化合物，结合另一种癌症治疗方法。这些化合物（IV）抑制TGF-β超家族成员如Nodal或Activin的信号传导。
• Binuclear molybdenum alkoxide as the versatile catalyst for the conversion of carbon dioxide
  作者：Jing-Huo Chen、Cheng-Hua Deng、Sheng Fang、Jian-Gong Ma、Peng Cheng

  DOI：10.1039/c7gc03372a

  日期：——

  The triply bonded dimolybdenum compound, Mo2(OtBu)6 (1), was investigated as a homogeneous catalyst for the conversion of CO2. The compound 1 acted as a rare example of a versatile catalyst with an impressive ability to transform CO2 into various valuable products, including propiolic acids, cyclic carbonates, and benzo[d]thiazole- and benzo[d]oxazolecarboxylic acids, in high yields with short reaction

  研究了三键结合的二钼化合物Mo 2（O t Bu）6（1）作为转化CO 2的均相催化剂。化合物1是多功能催化剂的稀有实例，具有令人印象深刻的能力，能够以高收率将CO 2转化为各种有价值的产物，包括丙酸，环状碳酸酯以及苯并[ d ]噻唑和苯并[ d ]恶唑羧酸。在环境压力和低温（25–75°C）下具有短的反应时间和出色的选择性。这是关于含金属-金属键的物质在CO催化转化中的首次报道。2。